Glucagon-Like Peptide-1 7-36 Amide and Peptide YY Have Additive Inhibitory Effect on Gastric Acid Secretion in Man

References

• Ali-Rachedi A, Varndell I M, Adrian T E, Peptide Y Y. (PYY) immunoreativity is costored with glucagon-related immuno-reactants in endocrine cells of the gut and pancreas. Histochemistry 1984; 80: 487–91
   PubMedGoogle Scholar
• Böttcher G, Sjölund K, Ekblad E, Håkanson R, Schwartz T W, Sundler F. Coexistence of peptide YY, and glicentin immuno-reactivity in endocrine cells of the gut. Regul Pept 1984; 8: 261–6
   PubMed Web of Science ®Google Scholar
• Solcia E, Riocca R, Capella C. Glucagon and PP-related peptides in intestinal L-cells and pancreatic/gastric A or PP cells. Possible interrelationships of peptides and cells during evolution, fetal development and tumor growth. Peptides 1985; 6: 233–9
   Google Scholar
• Böttcher G, Alumets J, Håkanson R, Sundler F. Co-existence of glicentin and peptide YY in colorectal L-cells in cat and man. An electron microscopic study. Regul Pept 1986; 13: 283–91
   PubMedGoogle Scholar
• Adrian T E, Ferri G L, Bacarese-Hamilton A J, Fuessl H S, Polak J M, Bloom S R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89: 1070–7
   PubMed Web of Science ®Google Scholar
• Ørskov C, Rabenhoj L, Kofod H, Wettergren A, Hoist J J. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994; 43: 535–9
   PubMed Web of Science ®Google Scholar
• Elliot R M, Morgan L M, Tredger J A, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7–36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159–66
   PubMedGoogle Scholar
• Layer P, Hoist J J. GLP-1: a humoral mediator of the ileal brake in humans?. Digestion 1993; 54: 385–6
   Google Scholar
• Pappas T N, Chang A M, Debas H T. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dog. Gastroenterology 1986; 91: 1386–9
   PubMed Web of Science ®Google Scholar
• Allen J M, Fritzpatrick M L, Yeats J C, Darcy K, Adrian T E, Bloom S R. Effect of peptide YY, and neuropeptide Y on gastric emptying in man. Digestion 1984; 30: 255–62
   PubMed Web of Science ®Google Scholar
• Schjoldager B GT, Mortensen P E, Christiansen J, Ørskov C, Hoist J J. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig Dis Sci 1989; 35: 703–8
   Google Scholar
• Wettergren A, Schjoldager B GT, Mortensen P E, Myhre J, Christiansen J, Hoist J J. Truncated GLP-1 (proglucagon 78–107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665–73
   PubMed Web of Science ®Google Scholar
• Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh S P, Hoist J J. Glucagon-like peptide-1 7–36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994; 29: 501–5
   PubMed Web of Science ®Google Scholar
• O'Halloran D J, Nikou G C, Kreymann B, Ghatei M A, Bloom S R. Glucagon-like peptide-1 (7–36).NH2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol 1990; 126: 169–73
   PubMedGoogle Scholar
• Savage A P, Adrian T E, Carolan G, Chatterjee V K, Bloom S R. Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 1987; 28: 166–70
   PubMed Web of Science ®Google Scholar
• Hobsley M, Silen W. Use of an inert maker (phenol red) to improve accuracy in gastric acid secretion studies. Gut 1969; 10: 787–95
   PubMed Web of Science ®Google Scholar
• Layer P, Hoist J J, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40: 1074–82
   PubMed Web of Science ®Google Scholar
• Olsen O, Christiansen J. Inhibition of human gastric acid secretion by peptide YY, and secretin. Digestion 1990; 47: 156–9
   PubMedGoogle Scholar
• Bado A, Cloarec D, Moizo L, Laigneau J P, Bataille D, Lewin M JM. Neurotensin and oxyntomodulin-(30–37) potentitate PYY regulation of gastric acid and somatostatin secretions. Am J Physiol 1993; 265: GU3–7
   Google Scholar
• Mogard M H, Maxwell V E, Syntnik B, Walsh J H. Regulation of gastric acid secretion by neurotensin in man: evidence against a hormonal role. J Clin Invest 1987; 80: 1064–7
   PubMed Web of Science ®Google Scholar
• Schjoldager B TG, Mortensen P E, Myhren J, Christiansen J, Hoist J J. Oxyntomodulin from the distal gut: role in regulation of gastric and pancreatic function. Dig Dis Sci 1989; 34: 1411–9
   PubMed Web of Science ®Google Scholar
• Wettergren A, Wøjdemann M, Meisner S, Stadil F, Hoist J J. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in man depends on an intact vagal innervation. Gut
   Google Scholar
• Pappas T N, Debas H T, Taylor I L. The enterogastrone-like effect of peptide YY is vagally mediated in dog. J Clin Invest 1986; 77: 49–53
   PubMedGoogle Scholar
• Nauck M, Ettler R, Niederreicholz U, Ørskov C, Hoist J J, Schmiegel W. Inhibition of gastric emptying by GLP-1 (7–36 amide) or (7–37): effects on postprandial glycemia and insulin secretion. Gut 1995; 37(Suppl 2)AI24
   Google Scholar
• Adrian T E, Savage A P, Sagor G R, Allen J M, Bacarese-Hamilton A J, Tatemoto K, et al. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 1985; 89: 494–9
   PubMed Web of Science ®Google Scholar